Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Radioimmunotherapy with alpha-particle emitting radionuclides Zalutsky MR; Pozzi ORQ J Nucl Med Mol Imaging 2004[Dec]; 48 (4): 289-96An important consideration in the development of effective strategies for radioimmunotherapy is the nature of the radiation emitted by the radionuclide. Radionuclides decaying by the emission of alpha-particles offer the possibility of matching the cell specific reactivity of monoclonal antibodies with radiation with a range of only a few cell diameters. Furthermore, alpha-particles have important biological advantages compared with external beam radiation and beta-particles including a higher biological effectiveness, which is nearly independent of oxygen concentration, dose rate and cell cycle position. In this review, the clinical settings most likely to benefit from alpha-particle radioimmunotherapy will be discussed. The current status of preclinical and clinical research with antibodies labeled with 3 promising alpha-particle emitting radionuclides - (213)Bi, (225)Ac, and (211)At - also will be summarized.|Actinium/*therapeutic use[MESH]|Alpha Particles/*therapeutic use[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Astatine/*therapeutic use[MESH]|Bismuth/*therapeutic use[MESH]|Humans[MESH]|Isotopes/therapeutic use[MESH]|Neoplasms/*radiotherapy[MESH]|Practice Patterns, Physicians'[MESH]|Radioimmunotherapy/*methods[MESH]|Radioisotopes/therapeutic use[MESH]|Radiopharmaceuticals/therapeutic use[MESH]|Treatment Outcome[MESH] |